Chemokine receptors on effector T cells

Chemokine receptors on effector T cells are a diverse group of G protein-coupled receptors (GPCRs) that play a fundamental role in the trafficking, homing, and positioning of activated T lymphocytes within tissues (nih.gov, 2025). These receptors, which include members of the CC and CXC subfamilies such as CXCR3, CCR5, and CCR4, recognize specific chemokine ligands produced at sites of inflammation or within the tumor microenvironment (aacrjournals.org, 2012). In the context of cancer, the expression of these receptors is critical for the infiltration of cytotoxic T cells into solid tumors, and their absence is a major barrier to effective immunotherapy (nih.gov, 2019). Conversely, in autoimmune and infectious diseases, these receptors can facilitate pathological cell recruitment or serve as co-receptors for viral entry, as seen with CCR5 and HIV (nih.gov, 2021). Therapeutic strategies include the use of small molecule antagonists like maraviroc to block viral entry or inflammation, and monoclonal antibodies like mogamulizumab to deplete specific T cell subsets in leukemia (mdpi.com, 2021). Additionally, engineering effector T cells to express specific chemokine receptors is an emerging approach to improve the homing of adoptive cell therapies to tumor sites (ijbs.com, 2019). The complexity and redundancy of the chemokine system present significant challenges for drug development, often requiring highly selective or multi-target approaches (frontiersin.org, 2025).

Other names

T cell chemokine receptorsEffector T cell chemokine receptorsChemokine receptor family

Drugs targeting these receptors primarily act as antagonists to block leukocyte recruitment or as monoclonal antibodies to deplete specific cell populations. Small molecule inhibitors often bind to allosteric sites within the transmembrane domain to prevent G protein signaling, while antibodies can block ligand binding or induce antibody-dependent cellular cytotoxicity (ADCC) (nih.gov, 2021; mdpi.com, 2021).